Company announces roadmap anchored by new two plate workflow enabling preparation of samples up to 2 million cells and beyond. New collaborations with Vizgen, BioLegend, and SPT Labtech will extend range.

A cutting-edge, high-density, energy efficient -80°C automated sample storage system.

SGD Pharma, announces its new range of high-quality Type I injectable vials in tubular glass with the added external low-friction coating developed by Corning thanks to an exclusive co-development partnership.

Collaboration aims to commercialize a Current Good Manufacturing Practice (cGMP) validated test to enable advanced and innovative analysis for multiple critical quality attributes of mRNA products.

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers. Single-plasmid transfection minimizes GMP plasmid costs and supply chain risk.

Longstanding Chairman of Lonza, Albert Baehny will not stand for re-election. Jean-Marc Huët, currently Chairman of Heineken N.V. with strong international leadership track record to be proposed as the new Chairman of Lonza at the 2024 AGM.

Lonza has reported sales of CHF 6.7 billion, sales growth of 7.9% AER2 (10.9%1 CER), and CHF 2 billion CORE EBITDA, resulting in a margin of 29.8%.

AMSBIO has launched a new 2024 travel grant award scheme for scientists under the age of thirty, employed in academia, research institutions, or companies engaged in cancer and stem cell research.

SGD Pharma, announces the opening of a new siliconization operation at its state-of-the-art Saint-Quentin Lamotte (SQLM) plant.

CELLBANKER® freezing media from AMSBIO is now available in customizable formats, seamlessly integrating into cell manufacturing processes with personalized formulations, volumes, and packaging.